Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

AbCellera Biologics, Inc.. (9/12/17). "Press Release: AbCellera Launches Antibody Discovery Collaboration with GSK". Vancouver, BC.

Organisations Organisation AbCellera Biologics Inc.
  Group AbCellera (Group)
  Organisation 2 GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Today GSK plc (LSE: GSK, NYSE: GSK)
  Group GSK (Group)
Products Product therapeutic antibody
  Product 2 drug screening (service)
Index term Index term GSK–AbCellera: therapeutic antibodies, 201709– collab discovery use of AbCellera technology + screening for Abs against membrane protein target
Person Person Hansen, Carl (AbCellera 201902 CEO)

AbCellera announces the initiation of a collaboration with GSK for the discovery of monoclonal antibodies against an undisclosed membrane protein target.

AbCellera Biologics, Inc. today announced that it has entered into an antibody discovery research collaboration with GSK, whereby AbCellera will apply its high-throughput single-cell antibody screening platform to identify antibodies against an undisclosed membrane protein target.

Over the past two years, AbCellera has established numerous collaborations with pharmaceutical and biotechnology companies working at the forefront of antibody drug discovery. “AbCellera is committed to providing innovative technology solutions that enable our collaborators to address their most challenging antibody-based programs. We are excited about the opportunity to work with GSK, one of the world’s leading science-led healthcare companies,” said Carl Hansen, President and CEO of AbCellera.

AbCellera will generate a panel of lead monoclonal antibodies against an integral membrane protein target using its single-cell technology enabling comprehensive screening of immune cells. GSK may then develop and market therapeutics derived from those discovered antibodies. Financial terms of the agreement were not disclosed.

About AbCellera Biologics Inc.

AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera’s lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates against a wide range of target classes from any species, including humans.


Kevin Heyries, 604-827-4151

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for AbCellera (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top